Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updates

YU-YUN SHAOHUNG-JU LIN2021-08-032021-08-0320211011-6842https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103459071&doi=10.6515%2fACS.202103_37%282%29.20210118B&partnerID=40&md5=4798de3dc77c2186d4760e2f8870623dhttps://scholars.lib.ntu.edu.tw/handle/123456789/575953Anticoagulation; Cancer; Deep vein thrombosis; Pulmonary embolism[SDGs]SDG3anticoagulant agent; apixaban; edoxaban; erythropoietin; glycoprotein; lenalidomide; low molecular weight heparin; rivaroxaban; tamoxifen; thalidomide; anemia; anticoagulation; female genital tract cancer; gastrointestinal hemorrhage; human; Letter; leukoCorrespondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updatesletter10.6515/ACS.202103_37(2).20210118B337164662-s2.0-85103459071